Enhancing Drug Safety Assessment with Automated Instrumentation in Secondary Pharmacology

Zhiying Nie,Yanan Zhao, Qiang Xia,Mingyang Yuan,Ziye Cui,Meihui Shi,Tiejjun Bing, Fujun Zhang, Xiao Guo, Ben Wei ICE Bioscience Inc, Beijing, China

ICESTP SAFETYPANELTM 90 Plus Dose Response : An optimized assay panel

Background

In the development of new drugs, it is crucial to know the safety profile of drug candidates in advance, as this can prevent the drug from being withdrawn from the market due to safety concerns after launch, thus reducing the risk for pharmaceutical companies.

It is estimated that approximately 75% of all adverse drug reactions (ADRs) are dose-dependent type A reactions, which can be predicted according to the pharmacological profiles of drug candidates. The pharmacological profiles are mainly divided into primary effects, which are related to the action of the compound at its intended target, and secondary effects, which arise from interactions with non-primary targets, i.e. off-target effects. Off-target interactions are often the cause of ADRs in animal models or clinical studies, so careful characterization and identification of the secondary pharmacological profiles of drug candidates early in the drug discovery process could help reduce the incidence of type A ADRs.

For this reason, we have established 100 screening models for the safety assessment of targets covering key areas such as the central nervous system, cardiovascular system, metabolism and immunity. The agonistic or antagonistic effects of compounds on these targets were evaluated by functional activity screening to evaluate the safety of compounds and to provide a reference point for late-stage drug discovery.



Figure 1: Mechanisms of drug action. To mediate a biological effect, a drug, or its metabolite(s), must bind to the primary therapeutic target or to other molecular targets. Only a small protein ligand interface region facilitates that interaction, thus off-target interactions may occur both at targets closely related to the therapeutic target or/and at structurally distinct targets. Secondary effects mediated by off-targets can be deleterious, beneficial or neutral.

Table: Advantages of ICESTP SAFETYPANEL[™] 90 Plus

Functional assay format	Ta
Ability to distinguish agonist and antagonist	Robust /reproducible
Ability to detect allosteric pharmacology	Ability to highlight par
Closed to the physiological situation. For example, 1 mM ATP used in kinase assays	Potential to highlight s
Provide for a more stringent analysis, resulting in fewer follow-up studies.	Quickly correlate with
Efficient and time-saving	Efficient and time-sav

References

[1]. Bowes, J. et al. Reducing safety-related drug attrition: the use of in vitro pharmacological profiling. Nat. Rev. Drug Discov. 11, 909-922 (2012)

[2]. Lynch JJ 3rd. et al. Potential functional and pathological side effects related to off-target pharmacological activity. J Pharmacol Toxicol Methods.; 87, 108-126(2017)

[3]. Richard J. Brennan. et al. The state of the art in secondary pharmacology and its impact on the safety of new medicines. Nat. Rev. Drug Discov. 23, 525-545 (2024)

ICESTP SAFETYPANEL[™] 90 Plus GPCR lon channel Kinases Transpoter Nuclear recepter

Figure 2. An overall composition of ICESTP SAFETYPANEL[™] 90 Plus

ICESTP SAFETYPANEL[™] 90 Plus provides 100 targets related to drug safety, which mainly consist of G protein-coupled receptors (GPCRs, 44 proteins) and 21 protein kinases, but it also includes 14 ion channels, 14 enzymes(non-kinase), three transporters and four nuclear receptors (Figure. 2a). ICESTP SAFETYPANELTM 90 Plus covering a wide range of target organ systems (Figure. 2b).



Compounds serial dilution by firefly





nL Compound transfer by Echo

Figure 3. Operation Process ICESTP SAFETYPANEL[™] 90 Plus Automated Equipment The ICESTP SAFETYPANEL[™] 90 Plus comprises 156 assays, integrating both single-point and dose-response screening methodologies within a functional assay framework, including techniques such as FLIPR Calcium Flux, HTRF, ADP-Glo, FP, etc. The utilization of SPT Labtech's firefly® automated liquid handling platform and acoustic liquid handler ECHO655 for high-throughput sample processing, thereby enhancing the efficiency and precision of safety assessments for the ICESTP 90 plus-target panel.

Pergolide tested by ICESTP SAFETYPANEL[™] 90 Plus

a. Pergolide Activation(%) and Inhibition(%) with functional assay format in ICESTP SAFETYPANEL[™] 90 Plus (Partial Data)



artial agonists solubility issues n in vivo exposure values

In vitro off-target screening: ICESTP SAFETYPANEL[™] 90 Plus





Reagents transfer by firefly



Read by Flipr



b. Pergolide activation or inhibition using dose response with function assay format in ICESTP SAFETYPANEL[™] **90 Plus Dose Response (Partial Data)**



c. Pergolide EC₅₀ or IC₅₀ with functional assay format in ICESTP SAFETYPANEL[™] 90 Plus (Partial Data)



Figure 4. Results of Pergolide tested in ICESTP SAFETYPANEL[™] 90 Plus Pergolide is a dopamine receptor agonist commonly utilized in the treatment of Parkinson's disease and other conditions, has been associated with an increased risk of cardiac valvulopathy, leading to its withdrawal from the US and Canadian markets in 2007. Using Pergolide as a case study(showed in Figure. 4a. and Figure. 4b.), we tested its off-target profile in ICESTP SAFETYPANELTM 90 Plus (showed in Figure. 4c), and subsequently utilized the off-target representation to elucidate its ADR mechanisms. It provide valuable information for safety-related prediction tasks. This early safety assessment protocol can steer a rational drug development process, facilitating the discovery of safe compounds.

- reactions of Peggotide.
- dystonia, etc.
- ✓ Other: Rhinitis, skin itching, edema, etc.

References:

- and heart failure.







M2-Agonist EC50 EC50>10000nM	5-H172B-Agonist EC50 EC50=2.634nM	5HT2B-Antagonist IC50 IC50<1.524nM	CB1-Agonist EC50 EC50>10000nM	CB1-Antagonist IC50 IC50>10000nM	D2S-Agonist ECS0 ECS0=0.555nM	D2S-Antagonist IC50 IC50=215.841nM	5-HT2C-Agonist EC50 EC50=3.313nM	5-HT2C-Antagonist ICS0 ICS0=9.15nM	CCK2-Agonist ECS0 ECS0>1000ehM	CCK2-Antegonist IC50 IC50>10000nM
	100-	100	100-	100	100-	100	100-	100-	100-	100-
		% uog 50	2° 50 -	2 2 50 -	50 Sec. 1	% ₩ 50-	2 50 - 1	5 Lugg 50	2 5 50-	۶ 50-
	Veliva				Vehra		Adiv			
	-50	-50	-50	-50	-50	-50	-50	.50	-50	50
100 10000 Pergolide, Conc., nM M3-Antagonist IC50	1 100 10000 Pergalide, Conc., nM CCK1-Aganist EC50	1 100 10000 Pergalide, Conc., nM COX1-hhibitar IC50	1 100 10000 Pergolide, Conc., nM CB2-Agonist EC50	1 100 10000 Pergalide, Conc., nM CB2-Antegonist IC50	0.01 1 100 Pergolide, Conc., nM op-delta-Agonist EC50	1 100 10000 Pergolide, Conc., nM VEGFR2-Inhibitor ICS0	1 100 10000 Pergolide, Conc., nM 5HT4AAgonist EC50	1 100 10000 Pergalide, Conc., nM 5-HT4A-Antegonist ICS0	1 100 10000 Pergelide, Conc., nM ETB-Agonist, EC50	1 100 10000 Pergelide, Conc., nM ETB Antagonist IC50
IC50>10000nM	EC50~10000nM	IC50>10000mM	EC50>10000mM	ICS0>10000nM	EC50>10000nM	ICS0>10000nM	ECS0>10000nM	ICS0>10000nM 150-	ECS0>10000nM	IGS0>10000nM
	100 -	100 - 2 ⁰	100- 2°	100 - #	100- 8°	100 - 2 ⁰	100 -	100-	100- %	100- 8
	- 03 - 03	50 - 50 -	50	99 50 - 10 -	0 = 50 - 10 = 50 - 10 = 50 = 50 = 50 = 50 = 50 = 50 = 50 =	0 - 19 - 19 -	Activation - 05	0 10 11 11 11 11 11	Activation	50- 101111111111111111111111111111111111
•	0-* * * * * * * * * *	•••••	0	•••••	0-* * * * * * * * *	• • • • • • • • •	0-* * * * * * * * * *	o- ••••	0-* * * * * * * * * *	••••••
100 10000 Pergolide, Conc., nM	-50 1 100 10000 Pergalide, Conc., nM	-50 1 100 10000 Pergalide, Canc., nM	-50 1 100 10000 Pergolide, Conc., nM	-50 - 1 100 10000 Pergalide, Conc., nM	-50 1 100 10000 Pergolide, Conc., nM	-50 1 100 10000 Pergolide, Conc., nM	-50 1 100 10000 Pergolide, Conc., nM	-50 1 100 10000 Pergolide, Conc., nM	-50 1 100 10000 Pergelide, Conc., nM	-50 1 100 10000 Pergelide, Conc., nM
PDE3A-Inhibitor IC50 IC50>10000nM	V1a-Agonist EC50 EC50>10000nM	MACA-Inhibitor IC50 IC50>10000mM	5-HT1AAgonist EC50 EC50=321.296nM 150-	5HT1A-Antagonist IC50 IC50>10000nM	PDE3A-Inhibitor IC50 IC50×10000mM 150	PDE4D2-Inhibitor IC50 IC50>10000nM	alpha 18-Agonist ECS0 ECS0>10000nM	alpha 1B-Antagonist ICS0 ICS0>10000nM 150-	M4-Agonist EC50 EC50>10000nM	GyRa1β-Agonist EC50 EC50>10000nM
	100-	100 -	100-	100 -	100 -	100 -	100 -	100-	100 -	100-
	≫ ⊑ 10 8 50 -	26	68 -	≱" uogiji 50 –	ू प 1001 - 60 -	8 ⁴	% 50-	% uo 19 19 19 19	50 - 50 -	8 5 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
	Q 0-0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	E	8 0- 	2 -0	s 0-• • • • • • • • • •	£	*	· · · · · · · · · · ·	2 0-• • • • • • • • • •	× • • • • • • • • • • • • • •
100 10000	-50 1 100 10000	-50 1 100 10000	-50 1 100 10000	-50 1 100 10000	.50 1 100 10000	-50 1 100 10000	-50 1 100 10000	-50 1 100 10000	-50 1 100 10000	-50 1 100 10000
Pergolide, Conc., nM 5HT2A-Antagonist IC50 IC50<1.524nM	H1-Agonist EC50 EC50>10000nM	H1-Antagonist IC50 IC50×10000nM	5HT1B-Agonist EC50 EC50=10.355nM	5HT1B-Antagonist IC50 IC50-10000nM	op-mu-Agonist EC50 EC50>10000rM	COX2-Inhibitor IC50 IC50>1000nM	alpha 28-Aganist ECS0 ECS0<1.524nM	alpha 28-Antagonist IC50 IC50<1.524nM	N5-Agonist ECS0 ECS0>1000M	N5-Antagonist IC50 IC50>1000mM
	100-	100-	100-	100-	100-	100-			100-	100-
	2 5 5 60-	% voi	50-	a" 50 -	2 ⁶ 51 50 -	8	% uoga 50-	2 ⁴	27 Dig 50 -	۶ 50-
			Vepro	0- ◆ _			Adiv	1 -		
	-50	-50	-50 - 1 - 1 - 1 - 1	.50	.50 1 1000	-50 4 400 4000	.50	50 1 100 1000	-50	50
Pergolide, Conc., nM	Percolide, Conc., nM	Demolide Core eM	Describe Once eM	Description of the second	Demolide Core ald	Description of the second	Description of the	10000	1 100 100	1 100 100
pha 1A-Antagonist IC50 IC50=152.577nM	β2-Agonist EC50 EC50>10000nM	5-HTT-Inhibitor IC50 IC50>1000nM	GR-Aganist EC50 EC50>10000nM	GR-Antagonist ICS0 ICS0<1.524nM	GABAA(a182/2)Aganist ECS0 ECS0×10000nM	GABA((c1)2/2)-Antagonist IC50 IC50×10000rlM	NK1-Agonist EC50 EC50>1000mM	Pergolide, Conc., nM SiK1-Antagonist EC50 IC50>10000nM	Pergolide, Conc., nM MC4-Agonist EC50 EC50>10000nM	Pergolide, Conc., nM MC4-Antagonist ICS0 ICS0>10000nM
pha 1A-Antagonist ICS0 ICS0=152.577nM	(82-Agonist EC50 EC50>10000nM	5+fTT/shhibior C50 IC50×10000nM	GR Against CC30 EC30-100004M	GR-Artagonist LOSO ICSO<1.524 rM	GABAV(e1β2 ₄ 2).Agorist ECS0 ECS0>10000nM	GABAV(a1)2/2)-Antagonist IC50 IC50>10000nM	NRI - Agonist ECS0 ECS0-10000nM	Pergolide, Conc., nM SK1-Antagonist ECS0 IC50-10000nM	MC4-Agonist EC50 EC50-10000M	MC4-Antagonist ICS0 ICS0-10000nM
pha 1AAvtagorist IOS0 DS0=152577nM	β2.4gonist ECS0 ECS0>1000-M β ⁰ 5	*##Udots_Coto_100 64/fTF#hibbor_C30 IC50+1000nM 100 100	Preparation, Caster, Internation, Caster, Internation, Caster, Internation, Caster, International Caster, Inte	Prington, Lonc., no P		Grievellog, Jone, no. Grievellog, Jone, no. ISO- ISO- 100- 6	- regarding Conc., mit	Perglide, Core, M SK1-Aregon IE 250 ISSo-10000mM 150 100- 4 ⁸ 5	MCA Apoint EC30 EC30=10000mM	MC4Aregorite (150 150- 100- 5
phe 14Aebgoriet 1250 E50+152377nM	82-Agonist ECS0 ECS8>1000044 100- 9 ² 50- 92	*#00006_0007_100 54/171*Hebbar C50 ICS0+10000rM	Preparation, Caller, Inte GR Agonetic EC50 EC50>10000-M	150 100 1	GNBVer[162]AGAL_TMFLC50 GNBVer[162]AGALTC50 ECS0-1000nM	GREATER CONTROL FOR THE CONTROL CONTROL OF CONTROL CON	- regarding Conc., no NRT	Perglids, Carc, M SK1-Aregonite IEC20 IS0- 150- 5 50- 6 9	MCA-Apoint EC50 HCA-Apoint EC50 HCA-Apoint EC50 HCA-Apoint EC50 HCA-Apoint EC50 HCA-Apoint EC50 HCA-Apoint HCA HCA-Apoint HCA-Apoint HCA HCA-Apoint HCA-Apoint HCA HCA-Apoint HCA-Apoi	MC4-Aregonic (S20) 1200- 100
C50+152.57hM	22 Agonis EC30 EC50>1000044 100		Preparation, Caster, Inv GR Agonetic EC50 EC50~10000reM 100- 26 50 50 0- 0- 0- 0- 0- 0- 0- 0- 0- 0	Preparation Conc., mil	GRUND COL, IN GRUND COL, IN GRUND ICCO ECCO-10000nM 100 0 0 0 0 0 0 0 0 0 0 0 0	GARANCE CARE, MAI GARANCE CARE, MAI GARANCE CARE, MAI ISO-10000M ISO-1000M ISO-1000M ISO-100M ISO-100M ISO		Perglida, Corc., Al 9(1)-4(2)-(2)-(2)-(2)-(2)-(2)-(2)-(2)-(2)-(2)-	MCA-Apoint EC30 IS0 100 0 0 0 0 0 0 0 0 0 0 0 0	Program, Lore, M
phs 19.4-etagorist 1250 1250-152.377nM		**************************************	Preparation Color_Inte GR Agenetic EC50 EC50>10000-MI 1000- 3 ² 0 - 20 - 20 20 - 20 - 20 	Preparation, Conc., nor 689. Areasonal ICS0 150 100 150 150 150 150 150 15	G484ve1(%2) Avenue EC30 F00 100 100 100 100 100 100 10	CoPercent Coperc	- registrate Color, not NRT Agenite ECS0 ECS0-10000+M 150 100 - - - - - - - - - -	Perglish, Carc, nM SK1-Aregonite IEC20 IS0- 150- 150- 150- 100- 150- 100- 1	Pergataba. Core., nM MCA.Aport EC50 EC50-10000-M 100	Programme, Corre., rM MC4-Areagenetic ISO ICSO-10000nM 100- 50- 50- 50- 50- 50- 100- 1
E9-152.57nM E9-152.57nM Pengolda, Conc., nM E10Ansports C50 ICS0-1000nM	22.Agonist ECS0 ECS0>100004M 100 100 1 1 10 1 1 10 1	- Hindback Color, International Color S-HTTHehibback Color 150 150 	Pergolide, Conc., rM 66 Agonisti EC50 EC50+10000rAM 100 100 100 100 100 100 100 10	Pergola, Core, no GR-Artagoniti ICS0 150 150 150 150 150 150 150 15	Network COND	CoPerturbation Come, min CoPERATION And AND AND AND AND AND AND AND AND AN	- Pergatalos, Color, Init NRT Agenia EES0 ECS0-1000eM 100 - 4 5 5 0 0 - - - 0 - - - - - - - - - - - - -	Perglide, Carc, rM	Pergalation, Care, nM MCA-Apoint EC30 EC50+10000rM 50 50 100 100 100 100 100 100	Pergalation, Carter, rM NC4-Pregaration (ESO) 100-
De 154-degoziel 1250 E59-152.57nM 100 Pendide Core, nM 10000 Pendide Core, nM 10000 E59-10000rd	B2-Apprint ECS0 ECS0-1000044 1000- 95 50- 	**************************************	Produce, Case, Int GR Agenetic EC50 EC50>1000eAd 150 0 0 0 0 0 0 0 0 0 0 0 0 0	Personal Conc., no	Control (Control (Contro) (Contro) (Contro) (Contro) (Contro) (Contro) (Contro) (Contro	Core and a constraint of the c		Perglish, Care, rM	Pergataba Core, M MCA Aport EC50 EC50-10000-M 100 - - - - - - - - - - - - - -	Program (LSPE, M) NC4-Register (LSD) 100- 50- 50- 50- 50- 0-a • • • • • • • • • • • • • • • 50- 0-a • • • • • • • • • • • • • • • • • • •
Pengolda, Conc., nM Pengolda, Conc., nM Pengolda, Conc., nM ETA-Assports CS0 ICS0+10000-nM	B2-Aponist ECS0 ECS0-1000044 100 50 50 50 50 50 50 100 100 100 100 1	Periodice_Conf_me 6-47T+4h-bitry_C50 150 100	Produce, Case, Int CRA Agonist EC60 EC50×100.004M 100 	Penglob, Core, no CR-Artagonit ICS0 ICS0-1524nM 150 150 150 150 150 150 150 150	0 0	100 10000 100000 10000 10000 <t< th=""><th>Pressoon Conc., niv NRT Agenise ECSO 150 100 - - - - - - - - - - - - -</th><th>Pergalida, Conc., nM SK1-Aregonite IEC20 150 150 150 150 150 150 150 15</th><th>Pergalide, Care, nM MCA-Apoint EC30 EC50+10000hM 100 </th><th>Program Love, M</th></t<>	Pressoon Conc., niv NRT Agenise ECSO 150 100 - - - - - - - - - - - - -	Pergalida, Conc., nM SK1-Aregonite IEC20 150 150 150 150 150 150 150 15	Pergalide, Care, nM MCA-Apoint EC30 EC50+10000hM 100 	Program Love, M
De 154-degoriel 1250 E59-152.57nM	B2-Apprint ECS0 ECS0-1000044 1000 9 ⁸ 50 	Pergodials Control 6-4177+6-hbar C50 LC50-10000rdM 100	Produce, Case_ Int CR4 Agents EC50 EC50>10000AM 1000- 3 ⁶ 0 0 0 0 0 0 0 0 0 0 0 0 0	Pergelon, Core, no GR Artagoli, CSO 150 100 100 100 100 100 100 100	Million, Dat., IM 0 0 0 ECS0-1000hM 100 - 0 -	Creating Concerns 100 Concerns 100 Concerns 100 Concerns 100 Concerns 100 Concerns 100 Concerns 100 Concerns 100 Percentiate Concerns 10000 Percentiate Concerns 10000 Percentiate Concerns 10000 Concerns 1000 Percentiate Concerns 10000 Concerns 1000 Percentiate Concerns 10000 Concerns 1000 Concerns 10000 Concerns 1000		Perglish, Carc, rM SK1-Aregonite IE200 L509-10000rM 100 	Pergataba Core, M MCA Aport EC50 EC50-10000-M 100 - 	McL4-Registric, Lotre, rM 100 ICSD-10000 hM 100 ICSD-10000 hM 100 ICSD-10000 hM 100 ICSD-10000 hM 0 ICSD-10000 hM 0 ICSD-10000 hM 100 ICSD-10000 hM
Des 14A-tegoriel ICS0 C50-152.57nM Pengolida, Conc., nM ETA-tegoriel ICS0 ICS0-1000nM Pengolida, Conc., nM	B. Agonist ECS0 ECS0-1000044 100 50 50 50 50 50 50 50 50 50 50 50 50 5	Pergodade_Color_Init 6-47T+4h-bitry C50 150 1000 10000 10000	Productor, Color, Int	Pergolation, Collec., nM	MR MARZING, CARL, 1M OFFWER(\$2,4) PARTIE CS00 1000 1000 1000 1000 1000 1000 10000	Colored Core, no. Colored Core,	NRT Agenite ECS0 1000 1000 1000 1000	Perglide, Carc, rM	Pergelia, Care, nM MCA-Apoint EC30 EC50+10000hM 100 	Pergelan, Care, rM NC4-Regulation (S20 100 100 100 100 100 100 100 1
Pergodia Conc., nM 100 Pergodia Conc., nM 100 Pergodia Conc., nM 1000 Pergodia Conc., nM 10000 Pergodia	B2-Apprint EC30 EC50=1000044 150 150 150 150 150 150 150 150	Pergodas Code, no 6-477-64-bibr C50 150 100 100 100 100 100 100 1	Produce, Case, Int	Preparison, Collec., no. Preparison, Collec	NEW 2004 Control New 2004	Carl 2-Hibbon Conc, MM Color (100)-March Color, MM Color (100)-March Col	Image: concernent and concernet and concernent and concernet and concernet and concernet and concernet and conc	Perglish, Care, rM SK1-Aregonic IE200 150 100 	Pergetado, Corre., MA MCA Aportal EE 200 EC50+10000+MI 100 	Perspine, Care, M MC4-Aregine, ICS0 100 100 50 0 4 00 100 100 100 100 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
De 15A-beggerist I250 E50+152.57nM	B2-Agonist ECS0 ECS0-1000044 150 150 150 150 150 150 150 150	Personal Conc., nm 150 150 150 150 150 150 150 150 150 16 17 18 19 1000 1000	Produce, Caller, Int	Pergola Conc., no CSD-150 100 100 100 100 100 100 100	NEW Project	Control (Control (Contro) (Control (Contro) (Control (Contro) (Contro) (Control (Con	NRT Aprile ECS0 100	Pergelide, Carc., rM SK1-Aregonite IEC20 ISO- 150- 150- 150- 150- 150- 150- 150- 150- 150- 150- 150- 150- 150- 150- 150- 10000 PM 10000 Pergelide, Carc., rM 10000 Pergelide, Carc., rM 10000 Pergelide, Carc., rM 10000 Pergelide, Carc., rM 10000 Pergelide, Carc., rM 10000 Pergelide, Carc., rM 10000 150-	Pergetide, Care, nM MCA Appril EC50 EC50+10000-MI 100 	Bit Description Descripacription Description
Pengdidi, C20 Pengdidi, C20 Pengdi	B Agonist ECS0 ECS0=1000044 100 100 100 100 100 100 1	Pergodas Code, no 6-477-64-bibr C50 ICS0-1000irdM 100 - - - - - - - - - - - - -	Produce, color, not 0 0 0 0 0 0 0 0 0 0 0 0 0	Personal Coller, Int GR Areason ICSO ISO-1524rM ISO	NEW264 (Sp2) April (Sc2) 90	Core Provide Core, nM Core Provide Core, nM Core Provide Core, nM Core Provide Core, nM Core Provide Core, nM Provide Core, nM Provide Core, nM Provide Core, nM Provide Core, nM Core Provide Core Provide Core, nM Core Provide Core, nM Core Provide Core, nM Core P	Image: constraint of the second sec	Perglish, Care, rM SK1-Aregonite IE200 ISO-10000rM ISO-100000 ISO-100000rM ISO-10000rM ISO	Hardshin, Core, M MCA Appendix EE 200 100 100 90 0	Perspine, Core, rM MC4-Aregorist (S20 100 100 50 0 40 0 40 100
De 15A-beggerist I250 E50+152.57nM	BAppoint ECS0 ECS0-10000M 150 150 150 150 150 150 150 150	Personal Conc., nm 150 150 100	Produce, Caller, Int	Pergelan, Core, no	NR NR 28 Aprixe CS0 100 -	Critery States Core, INA Critery States Core, INA Conversion Conver	NRT Aprile ECS0 100	Pergetide, Care, rM	Pergelab. Core, nM MCA Apprist EC50 100 100 00 00 00 100 <t< th=""><th>Pergnine, Care, rM 100 NC4-Aragonic IS30 IC50-10000 M 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 0 - 0 - 0 - 0 - 0 - 0 - 0 - 0 - 0 - 0 - 0 - 0 - 0 - 0 - 0 - 0 -<!--</th--></th></t<>	Pergnine, Care, rM 100 NC4-Aragonic IS30 IC50-10000 M 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 100 - 0 - 0 - 0 - 0 - 0 - 0 - 0 - 0 - 0 - 0 - 0 - 0 - 0 - 0 - 0 - 0 - </th
Persodia Conc., mM Persodia Conc., mM Persod	B B B B B B B B B B B B B B	Produce Conc. International Conc. Internationa	Produktion, Calibia, Inter	Preparing Conc., nm 150 150 150 150 150 150 150 150	NEW264 (Sp2) April (ESD) 90	Core 1000 core, m/d Core 1000 core 10	Image: constraint of the second sec	Perglish, Care, rM SK1-Aregonite IE200 LS9-10000rM 100 - 0 - 0 - 0 - 0 - 0 - 0 - 0 -	Hardshin, Carle, M MCA Appendix EE20 100 100 90 0	Perspine, Care, rM MC4-Aregorist IS20 100 100 50 0 60 100 0
Pergolial, Core, nM 1000 Pergolial, Core, nM 10000 Pergolial, Core, nM 1000 Pergolial, Core, NM	BAppoint ECS0 ECS0-10000M 150 150 150 150 150 150 150 150	Pergodade_Core_nim 6-47T+4h-bitry C50 150 100	Production_Color	Pergelok, Core, nM	NEW 2000 CONT IN 000 000 ECS0+10000hM ECS0 100 0 0 0 0 100 0 0 0 0 0 100 0 0 0 0 0 0 100 0 0 0 0 0 0 0 100 0	Control (Control (Contro) (Control (Contro) (Contro) (Contro) (Contro) (Con	NRT Aprile ECS0 100	Pergetide, Carec., MI	Pergetide, Care, nM MCA Apprist ES0 ECS0+10000-MI 50 50 50 50 50 50 50 50 50 50	Pergnine, Care, rM 100 NC4-Aragonic ISS0 ISS0-10000 M 100 100 100 100 100 100 100 100 100 100 100 1000 100 1000 100 1000 100 Pergnide, Care, rM 100 1000 100 Pergnide, Care, rM 100 10000 100 Pergnide, Care, rM 100 10000 100 10000 100 10000 100 10000 100 10000 100 10000 100 10000 100 10000 100 10000 100 10000 100 10000 100 10000 100 10000 100 10000 100 10000
Pin 54Aresports L50 E50-152.57nM Pingolds, C50 E50-152.57nM Pingolds, C50 E50-152.57nM Pingolds, C50 E50-150.000 Pingolds, C50 E50-152.57nM Pingolds, C50 E50-152.57nM Pingolds, C50 E50-152.57nM Pingolds, C50 E50-152.57nM	B Agonist ECS0 ECS0=10000MI	Personal Conc., nm 100 - 1000 <td< th=""><th>Netzkala, Calk_ IN 06R. Agenit ECs0 100 100 0</th><th>Personal Code _ not CR Areason ICSO ISO-1.524rM ISO-1.</th><th>NPL Model Control NPL Model Control NPL Model Control NPL Model Control NPL Model NPL Mo</th><th>Cart 2 Histor Conc. mil</th><th>Image: constraint of the second sec</th><th>Perglish, Care, M SKI-Aregonic IE200 150 150 100 100 100 100 100 1</th><th>MCA Apprist ECSO MCA Apprist ECSO MCA Apprist ECSO MCA Apprist ECSO MCA Apprist ECSO ECSO-10000-MI 100 </th><th>Image Description Description 100 NC4 Areagonic ICS0 ICS0+10000 MI 100 100 100 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 100 1000 Peradide, Care, nM 10000 <t< th=""></t<></th></td<>	Netzkala, Calk_ IN 06R. Agenit ECs0 100 100 0	Personal Code _ not CR Areason ICSO ISO-1.524rM ISO-1.	NPL Model Control NPL Model Control NPL Model Control NPL Model Control NPL Model NPL Mo	Cart 2 Histor Conc. mil	Image: constraint of the second sec	Perglish, Care, M SKI-Aregonic IE200 150 150 100 100 100 100 100 1	MCA Apprist ECSO MCA Apprist ECSO MCA Apprist ECSO MCA Apprist ECSO MCA Apprist ECSO ECSO-10000-MI 100 	Image Description Description 100 NC4 Areagonic ICS0 ICS0+10000 MI 100 100 100 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 100 1000 Peradide, Care, nM 10000 0 <t< th=""></t<>
phe 14Aespeciel ICS0 C50+152.57nM Pengolida, Conc., nM Pengolida, Conc., nM Pengolida, Conc., nM	B Agonist ESS ESSP-10000M	Pergodade_Conc., nm 150 150 100 <th>Produce, Caller, Int</th> <th>Personal Color, no Personal Color, no CR Areasonic ICS0 ICS0-1.524 rM</th> <th>NR 285 April ECS0 100 -</th> <th>Control (100) - 10000 - 10000 - 1000</th> <th>NRT Aprile ECS0 100</th> <th>Pergetide, Care, rM SK1-Aregonic IEC20 150 100 </th> <th>Pergetide. Core., nM MCA Apprint ECS0 100 ECS0+10000-MI 90 0</th> <th>Perspine Conc., rM 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 1000 100 1000 100 1000 100 Perspila 100 Perspila</th>	Produce, Caller, Int	Personal Color, no Personal Color, no CR Areasonic ICS0 ICS0-1.524 rM	NR 285 April ECS0 100 -	Control (100) - 10000 - 10000 - 1000	NRT Aprile ECS0 100	Pergetide, Care, rM SK1-Aregonic IEC20 150 100 	Pergetide. Core., nM MCA Apprint ECS0 100 ECS0+10000-MI 90 0	Perspine Conc., rM 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 1000 100 1000 100 1000 100 Perspila
Penglida, Core, nM Penglida, Core, NM Pengli	B Agonist EC30 EC50-10000M	Personal Conc., nm 100	Netbolic Color Netbolic Netbolic <t< th=""><th>Personal Code, not CR-Arespondent CS50 ISG0-1,524 rM ISG0-1,524 rM ISG0-1,524</th><th>NPL Model Control Contro Control Control <</th><th>Cart 2 Hibbox Core, nM GREAT Core 1000 100 100 100 100 100 100 100</th><th>Image: constraint of the second sec</th><th>Perglish, Care, M SKI-Aregonic IEC20 150 100 - - - - - - - - - - - - -</th><th>MCA Appeint EX0 100 100 100 0 0 0 0 0 0 0 0 0 0 0 0</th><th>Perspine Conc., nM 100 100 100 100 00 100 00 100 00 100 00 100 00 100 100 1000</th></t<>	Personal Code, not CR-Arespondent CS50 ISG0-1,524 rM ISG0-1,524	NPL Model Control Contro Control Control <	Cart 2 Hibbox Core, nM GREAT Core 1000 100 100 100 100 100 100 100	Image: constraint of the second sec	Perglish, Care, M SKI-Aregonic IEC20 150 100 - - - - - - - - - - - - -	MCA Appeint EX0 100 100 100 0 0 0 0 0 0 0 0 0 0 0 0	Perspine Conc., nM 100 100 100 100 00 100 00 100 00 100 00 100 00 100 100 1000
на ИАнарука ICS0 IC80-1925770M 00 Pergelda, Corc., nM 10000 Регазиа, Corc., nM 10000 Регази 10000 10000 10000 10000 10000 10000 10000 10000 10000 10000 10000 100000 10000 10000 10000 10000 10000 10000 10000 10	B ² Agonist ECS0 ECS0=10000M	Periodical Conc., nM 150 100 <td>Produce, Case, Int</td> <td>Personal Code, not Personal Code, not CR4 Areasonal CS50 EC30-1.524 rM 100 </td> <td>NR 282 April EC30 100 -</td> <td>Control (100) - Market (100) - Marke</td> <td>NRT April ECS0 100</td> <td>Pergetide, Care, rM SK1-Aregonic IEC20 150 100 </td> <td></td> <td>Perspine Conc., rM 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 1000 100 1000 100 1000 100 1000 100 1000 100 1000 100 1000 100 1000 100 1000 100 1000 100 1000 100 1000 100 1000 100 1000 100 1000 100 1000 100 1000 100 1000</td>	Produce, Case, Int	Personal Code, not Personal Code, not CR4 Areasonal CS50 EC30-1.524 rM 100 	NR 282 April EC30 100 -	Control (100) - Market (100) - Marke	NRT April ECS0 100	Pergetide, Care, rM SK1-Aregonic IEC20 150 100 		Perspine Conc., rM 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 1000 100 1000 100 1000 100 1000 100 1000 100 1000 100 1000 100 1000 100 1000 100 1000 100 1000 100 1000 100 1000 100 1000 100 1000 100 1000 100 1000 100 1000



/ Based on the test results, we attempt to provide potential explanations for the various adverse reactions caused by off-target

✓ Cardiovascular system: Orthostatic hypotension (incidence rate of about 9%), palpitations, tachycardia, congestive heart failure,

/ Nervous system: Dyskinesia (incidence rate of about 62.4%), hallucinations, insomnia (incidence rate of about 7.9%), dizziness,

/ Gastrointestinal system: Nausea (incidence rate of about 24.3%), vomiting, constipation, diarrhea, etc.

• "Serotonin 5-HT2B receptor agonism and valvular heart disease: implications for the development of psilocybin and related agents" Expert Opinion on Drug Safety, 2023. The article mentions that Pergolide may lead to heart valve pathology as evidenced by thickening of the valves and restriction of movement, which in turn can lead to regurgitation of blood, pulmonary hypertension

• "Dopamine D2, but not D4, receptor agonists are emetogenic in ferrets". Pharmacology, Biochemistry, and Behavior, 81, 211–219. (2005). This literature indicates that dopamine D2 receptor agonists trigger a strong emetic response in ferrets and gives the mechanism of emesis; it can explain the gastrointestinal side effects of Pergolide (such as vomiting, diarrhea).